At the same time, although SIRT7 inactivates p53 by deacetylation, up to half of all tumors exhibit mutated p53, which may diminish the oncogenic role of SIRT7 and result in tumor suppressive characteristics (83, 90). Here, TP53 is linked to neoplasm.